

Source

FITC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with FMC63.

Isotype

Mouse IgG1/kappa

Specificity

Specifically recognizes the antigen-recognition domain of FMC63 derived CARs.

Conjugate

FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm

Labeling

The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.

Protein Ratio

The FITC to protein molar ratio is 1-2.

Application

Flow Cytometry (Evaluation of Anti-CD19 (FMC63 scFv) CAR Expression).
*The Isotype control (Cat. No. [DNP-FM1A1](#)) is sold separately and you can follow [this link](#) for product information.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.

Reconstitution


Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:

- 20°C to -70°C for 24 months in lyophilized state;
- 70°C for 12 months under sterile conditions after reconstitution.

Bioactivity-FACS



FITC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45)

Catalog # FM3-FY45



2e5 of Anti-CD19 CAR-293 cells were stained with 100 μ L of 1:50 dilution (2 μ L stock solution in 100 μ L FACS buffer) FITC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (Cat. No. FM3-FY45) and isotype control respectively. FITC signal was used to evaluate the binding activity (QC tested).

Background

FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.

Clinical and Translational Updates

Discounts, Gifts,
and more!

